Skip to main content

Find Clinical Trials

Home
Conditions
Relapsed / Refractory AML

Clinical trial condition

Relapsed / Refractory AML

Explore clinical trials studying Relapsed / Refractory AML. Study availability and eligibility vary by location and protocol.

3 public trials 1 recruiting study

Refine in advanced search Browse all conditions

Relapsed / Refractory AML trial results

Recruiting

Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax

NCT07471841

Conditions: Hematologic Diseases, Hemic and Lymphatic Diseases, IDH1 Mutation, +6 more
Locations: Atrium Health Wake Forest Baptist Medical Center Winston-Salem, North Carolina, United States

View Trial Details

Not Yet Recruiting

Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN

NCT07710534

Conditions: Hematologic Diseases, Hemic and Lymphatic Diseases, High Risk Myelodysplastic Syndrome, +7 more
Locations: Virginia Commonwealth University Richmond, Virginia, United States

View Trial Details

Active, Not Recruiting

Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms.

NCT06359002

Conditions: Disease Attributes, Hematologic Diseases, Hematologic Neoplasms, +12 more
Locations: Het Ziekenhuisnetwerk Antwerpen Antwerp, Belgium

UZ Leuven Leuven, Belgium

Universitair Medisch Centrum Groningen Groningen, Netherlands

Institut Catala d'Oncologia Badalona, Spain

View Trial Details